Auven Therapeutics, a private equity firm focused on the development of breakthrough drugs, said Tuesday that it has sold Spirogen to MedImmune, a research and development unit of AstraZeneca. As part of the transaction, MedImmune will purchase a 100% stake in Spirogen for $200 million in cash.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
